PENTAX Medical America, a division of the HOYA Group, is proud to announce two significant updates to its C2 CryoBalloon product line. These advancements are designed to enhance patient care and expand treatment options for gastroenterologists.
1. 180° C2 CryoBalloon Catheter for Barrett’s Esophagus:
- Increased Treatment Area and Efficiency: The 180° C2 CryoBalloon Catheter is the first cryogenic product specifically designed to treat large areas of Barrett’s esophagus. The unique 180° design allows gastroenterologists to cover larger areas quickly, reducing the overall procedure time. This establishes the C2 CryoBalloon 180° as an ablative therapy that treats large tissue areas, minimizes patient discomfort, and demonstrates 90% disease regression at the first surveillance visit.
2. New Clinical Indication for Gastric Antral Vascular Ectasia (GAVE):
- Less Painful Treatment Option: The C2 CryoBalloon solution now offers a novel treatment for GAVE. This minimally invasive cryogenic technology proves to be a less painful alternative to existing available treatment. C2 CryoBalloon System targets affected areas with quick precise cryotherapy, minimizing the need for frequent packed red blood cell transfusions at 6 months when compared to existing treatment modalities.
- FDA Clearance: PENTAX Medical has obtained FDA clearance for the use of the C2 CryoBalloon system in treating GAVE. This clearance confirms the system’s safety and efficacy, offering gastroenterologists a new tool to enhance patient care.
“The introduction of the 180° C2 CryoBalloon Catheter and the new indication for GAVE treatment represent significant advancements in patient care.” This was emphasized by David Hedrick, Senior Director of the C2 CryoBalloon Franchise. “These innovations not only provide more effective and less painful treatment options but also greatly expand the application of the C2 CryoBalloon technology. By offering faster and safer procedures, we are enhancing the quality of life for patients and giving gastroenterologists powerful new tools to address complex conditions.”
